• KOL
    • Chronic Hepatitis
    • Peter Ferenci
    • Peter Ferenci: Influence Statistics

      Peter Ferenci

      Peter Ferenci

      Show email address

      Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria. | Medizinische Universität Wien, Austria. | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Peter Ferenci:Expert Impact

      Concepts for whichPeter Ferencihas direct influence:Chronic hepatitis,Hepatic encephalopathy,Wilson disease,Liver disease,Hepatocellular carcinoma,Hcv genotype,Antiviral therapy,Portal hypertension.

      Peter Ferenci:KOL impact

      Concepts related to the work of other authors for whichfor which Peter Ferenci has influence:Hepatic encephalopathy,Chronic hepatitis,Hepatocellular carcinoma,Liver disease,Hcv infection,Pegylated interferon,Cirrhotic patients.

      KOL Resume for Peter Ferenci

      Year
      2022

      Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.

      2021

      Vienna, Austria

      2020

      Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Austria

      2019

      Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Vienna, Austria

      2018

      Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

      2017

      Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

      2016

      Universitaetsklinik fuer Innere Medizin III Vienna Austria

      World Gastroenterology Organisation, Milwaukee, WI

      Ira Jacobson, Weill Cornell Medical College, New York, NY 10029, United States.

      2015

      Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria

      2014

      Rawalpindi Medical College, Rawalpindi, Punjab, Pakistan

      Medical University of Vienna, Vienna General Hospital (AKH) Department of Internal Medicine III (Gastroenterology and Hepatology) Vienna Austria

      Carver College of Medicine, University of Iowa, Iowa City, IA

      2013

      Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria.

      Internal Medicine 3, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

      2012

      Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria

      Univ. Klinik für Innere Medizin 3, Klin. Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien

      2011

      Gastroenterology & Hepatology, Internal Medicine III, Medical University Vienna, Waehringergürtel 18 - 20, Vienna, 1090, Austria

      University of Vienna, Vienna (P.F.)

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Peter Ferenci is among the top experts in the world.
      Concept World rank
      atp7b gene c3207ag #1
      il28b ip10 #1
      hcv genotype rna #1
      c2530a #1
      sil viral replication #1
      interferonα chronic hepatitis #1
      copper organs #1
      pgly1341asp #1
      standard ifn loss #1
      ctm ver #1
      antiviral therapy analysis #1
      minimal summary #1
      pegifn rbv anc #1
      symptoms ifn therapy #1
      combination simeprevir daclatasvir #1
      benzodiazepine receptors parameters #1
      patients study patients #1
      fib4 aucs #1
      88 complete evrs #1
      vwfag score #1
      glycols polymerase #1
      svr12 rates comedications #1
      fibrosis vwfag #1
      neural excitation brain #1
      drug therapy internationality #1
      540 pg #1
      ribavirin epo #1
      120 faldaprevir #1
      cirrhosis ifn therapy #1
      g1 4 patients #1
      rat liver gaba #1
      patients glucose supply #1
      chronic homozygote humans #1
      wd weightbased dosages #1
      virological response weeks #1
      ctm ver art #1
      subcutaneous instillation pei #1
      4‐infected patients #1
      sof ldvrbv #1
      wd austria #1
      gp73 expression p005 #1
      viral ribavirin ifn #1
      ash mcv #1
      cervicocranial transmission #1
      interferon‐α ribavirin #1
      chc hhc #1
      silymarin treatment patients #1
      hgv coinfection patients #1
      east german patients #1
      cepict control studies #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Peter Ferenci

      KOL-Index: 24489

      BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial data for treatment remain limited. We assessed the combination of two direct-acting antivirals, ombitasvir (NS5A inhibitor) and paritaprevir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV ...

      Known for 4 Infection | Patients Hcv Genotype | Ritonavir Ribavirin | 12 Weeks | Treatment Week
      KOL-Index: 20600

      BACKGROUND: In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment.

      METHODS: A total of 334 patients who had chronic infection with HCV genotype 1 and had not been treated previously were randomly assigned to receive one of four treatments ...

      Known for Peginterferon Ribavirin | Chronic Hcv | 12 Weeks | Sustained Virologic Response | Pr48 Rate
      KOL-Index: 19851

      Peginterferon alfa-2a results in a sustained response (SR) in a minority of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). This study investigated the role of early on-treatment serum hepatitis B surface antigen (HBsAg) levels in the prediction of SR in HBeAg-negative patients receiving peginterferon alfa-2a. HBsAg (Architect from Abbott) was quantified at the baseline and during treatment (weeks 4, 8, 12, 24, 36, and 48) and follow-up (weeks 60 and 72) ...

      Known for Hbv Dna | Peginterferon Alfa‐2a | Antigens Hepatitis | Treatment Hbsag | Sustained Responders
      KOL-Index: 19213

      BACKGROUND & AIMS: It is unclear whether the magnitude of reduction in hepatitis C virus (HCV) RNA between baseline and week 4 of treatment influences the probability of achieving a sustained virological response (SVR) in patients without a week 4 rapid virological response (RVR).

      METHODS: Data were retrospectively analyzed from two studies in which treatment-naive patients received peginterferon alfa-2a (40KD) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks. Five hundred and ...

      Known for Week 4 Response | 1 Patients | Hcv Rna | Rvr Svr | Studies Ribavirin
      KOL-Index: 19087

      BACKGROUND & AIMS: This randomized multicenter trial evaluated individualization of treatment duration with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day in patients with chronic hepatitis C genotype 1/4 based on the rapidity of virologic response (VR).

      METHODS: Patients with a rapid VR (RVR; undetectable hepatitis C virus [HCV]-RNA level (<50 IU/mL at week 4) were treated for 24 weeks, those with an early VR (EVR; no RVR but undetectable HCV-RNA level or ...

      Known for 72 Weeks | 4 Patients | Virologic Response | Peginterferon Ribavirin | Svr Rate
      KOL-Index: 19073

      BACKGROUND & AIMS: Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection. We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon-α2a (PegIFN), and ribavirin (RBV) in patients with HCV genotype-1 infection previously treated with PegIFN and RBV.

      METHODS: We analyzed data from patients who did not respond (null ...

      Known for Pegifn Rbv | Patients Simeprevir | Sustained Virologic Response | Phase Iib | 24 Weeks
      KOL-Index: 18022

      BACKGROUND & AIMS: The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide. We evaluated whether ribavirin is necessary for ABT-450, ritonavir, ombitasvir, and dasabuvir to produce high rates of sustained virologic response (SVR) in these ...

      Known for 1b Infection | Hcv Genotype | Ribavirin Patients | Ritonavir Ombitasvir | Virologic Response
      KOL-Index: 17242

      Approximately one third of hepatitis C virus (HCV) genotype 1 patients achieved a sustained virological response (SVR) after 24 weeks of treatment with peginterferon alpha-2a (40 kd) plus ribavirin in a randomized, multinational trial. We aimed to identify factors associated with a rapid virological response (RVR) at week 4 (HCV RNA <50 IU/mL) and a SVR (HCV RNA <50 IU/mL at the end of follow-up) in these patients. Stepwise multiple logistic regression analysis was used to explore the ...

      Known for 24 Weeks | 1 Patients | Hcv Genotype | Early Identification | Svr Rvr
      KOL-Index: 16497

      BACKGROUND & AIMS: This analysis reports the rate of sustained virological response (SVR) in patients infected with hepatitis C virus (HCV) genotype 1 or 4 who were assigned to 24 weeks of treatment with pegylated interferon (peginterferon) alfa-2a 180 mug/wk plus ribavirin 1000/1200 mg/day after achieving a rapid virological response (RVR; HCV RNA level <50 IU/mL) at week 4 in a prospective trial investigating response-guided therapy.

      METHODS: Non-RVR patients with an early virological ...

      Known for 24 Weeks | Rapid Virological Response | Patients Rvr | Hcv Genotype | Svr Rate
      KOL-Index: 16207

      BACKGROUND & AIMS: We aimed to investigate the impact of sustained virologic response (SVR) to interferon (IFN)-free therapies on portal hypertension in patients with paired hepatic venous pressure gradient (HVPG) measurements.

      METHODS: One hundred and four patients with portal hypertension (HVPG ⩾6mmHg) who underwent HVPG and liver stiffness measurement before IFN-free therapy (baseline [BL]) were retrospectively studied. Among 100 patients who achieved SVR, 60 patients underwent HVPG ...

      Known for Portal Hypertension | Patients Hvpg | Sustained Virologic Response | Liver Stiffness | Transient Elastography
      KOL-Index: 15587

      BACKGROUND: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.

      METHODS: We conducted a study involving patients with HCV genotype 2 or 3 infection, some of whom had undergone previous treatment with an interferon-based regimen. We ...

      Known for Hcv Genotype | 3 Infection | 12 Weeks Patients | 24 Weeks | Response Rates
      KOL-Index: 15580

      Reduced hepatobiliary transporter expression could explain impaired hepatic uptake and excretion of bile salts and other biliary constituents resulting in cholestasis and jaundice. Because little is known about alterations of hepatobiliary transport systems in human cholestatic liver diseases, it was the aim of this study to investigate such potential changes. Hepatic mRNA levels in hepatobiliary transport systems for bile salts (NTCP, BSEP), organic anions (OATP2, MRP2, MRP3), organic ...

      Known for Transporter Expression | Bile Salts | Ntcp Bsep | Cholestatic Liver Diseases | Hepatobiliary Transport
      KOL-Index: 15471

      BACKGROUND & AIMS: Little is known about substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments.

      METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (nonstructural protein [NS]3, NS5A, NS5B) targeted by DAAs. We compared ...

      Known for Patients Treatment Failure | Rass Ns5a | Hcv Genotype | Acting Antivirals | Daclatasvir Ledipasvir
      KOL-Index: 15383

      BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in IL28B and serum levels of interferon γ inducible protein 10 (IP-10) predict outcomes of antiviral therapy in patients with chronic hepatitis C. We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC).

      METHODS: We studied 120 patients with AHC (64 male; 37 ± 16 years old) and 96 healthy individuals (controls). The IL28B SNPs rs12979860 and ...

      Known for Spontaneous Clearance | Serum Level | Il28b Polymorphisms | Acute Hcv Infection | Patients Ahc
      KOL-Index: 15105

      BACKGROUND & AIMS: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with <2log hepatitis B virus (HBV) DNA decline at week 12 of a 48-week peginterferon alfa-2a (PEG-IFN) treatment course achieved a sustained response (SR). We aimed at validating this stopping rule in two independent trials.

      METHODS: HBeAg-negative patients receiving 48 or 96 weeks of PEG-IFN in the phase III ...

      Known for Hbv Dna | Stopping Rule | Negative Patients | Week 12 | Hbsag Decline

      Key People For Chronic Hepatitis

      Top KOLs in the world
      #1
      Patrick Marcellin
      chronic hepatitis adefovir dipivoxil hcv genotype
      #2
      Michael Peter Manns
      chronic hepatitis liver transplantation hepatocellular carcinoma
      #3
      Anna Shuk‐Fong Lok
      chronic hepatitis hepatocellular carcinoma united states
      #4
      Stefan S Zeuzem
      chronic hepatitis hcv genotype liver fibrosis
      #5
      Jay H Hoofnagle¶¶
      chronic hepatitis liver injury united states
      #6
      Zachary D Goodman
      chronic hepatitis liver fibrosis hepatocellular carcinoma

      Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria. | Medizinische Universität Wien, Austria. | Vienna, Austria | Division of Gastroenterology and Hepatology, Department of In

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.